Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized study

Vedamurthy Reddy Pogula, Lalith Sagar Kadiyala, Vijayabhaskar Reddy Gouru, Sivasankar Reddy Challa, Ranadheer Byram, Sudeep Bodduluri

Department of Urology and Renal Transplantation, Narayana Medical College and Hospital, Nellore, Andhra Pradesh, India

Citation: Pogula VR, Kadiyala LS, Gouru VR, Challa SR, Byram R, Bodduluri S. Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized study. Cent European J Urol. 2019; 72: 44-50.

INTRODUCTION

Benign prostatic hyperplasia (BPH) is highly prevalent in elderly men and often results in lower urinary tract symptoms (LUTS). LUTS secondary to BPH increases with age and negatively impacts patients’ quality of life. The current standard of care in men with moderate to severe LUTS secondary to BPH is treatment with alpha-blockers or in men with enlarged prostates with 5-alpha-reductase inhibitors either alone or in combination and transurethral surgery in those who have failed medical therapy [1-4]. Erectile dysfunction (ED) is a highly prevalent comorbidity in men with LUTS secondary to BPH. The observation that men with ED in general have greater LUTS suggests a common etiology [5]. The negative impact of LUTS and ED on the quality of life of aging men has been well acknowledged in the literature. The phosphodiesterase type-5 (PDE5-I) inhibitor tadalafil has recently received approval in the USA and European Union for the treatment of LUTS secondary to BPH, with or without erectile dysfunction (ED) [1,2]. The aim of this study is to compare the effect of tadalafil 5 mg with tamsulosin 0.4 mg on LUTS secondary to BPH.

MATERIAL AND METHODS

This is a prospective, randomized study included 100 patients with LUTS secondary to BPH. The
The analysis was done using paired sample t-test and independent sample t-test. Treatment group differences and changes from baseline to end of therapy in Qmax, PVR, IPSS, IPSS QoL and SHIM score were analysed [6].

RESULTS

In the present study, LUTS secondary to BPH was commonly seen in the age groups of 51–60 and 61–70 years. The mean age was (59.40 ±8.84) years in the tadalafil group and (63.66 ±9.05) years in the tamsulosin group. A total of 21 (42%) patients were hypertensive in the tadalafil group and 15 (30%) patients in the tamsulosin group. Diabetes mellitus patients totaled 16 (32%) in the tadalafil group and 17 (34%) in the tamsulosin group. In the present study, in the tadalafil group, 23 (46%) patients had a prostate gland size less than 30 g and 27 (54%) patients had a prostate gland size more than 30 g. In the tamsulosin group, 28 (56%) patients had a prostate gland size less than 30 g and 22 (44%) patients had a prostate gland size more than 30 g. In the tadalafil group, 12 (24%) patients had mild LUTS and 38 (76%) had moderate LUTS. In the tamsulosin group, 9 (18%) patients had mild LUTS and 41 (82%) patients had moderate LUTS. Seventeen (34%) patients had associated ED in the tadalafil group and 13 (26%) patients had associated ED in the tamsulosin group. In this study, 4 patients received washout therapy in the tadalafil group and 6 patients in the tamsulosin group.

Baseline (BS) characteristics of both the groups recorded at day 0 of the trial were compared and are presented in Table 1. Parameters such as age, prostate volume (g), total IPSS score, quality of life score, maximal urinary flow rate and residual urinary volume were not significantly different between both groups (Table 1). In the present study, both the groups showed a response to the treatment after 1 week of initiation. The group receiving tadalafil showed a response in all the parameters with no statistical value. The group receiving tamsulosin showed a significant change in Qmax and PVR but not in IPSS and IPSS-QoL after 1 week of treatment. After 4 weeks of initiation, both the groups showed response in all the efficacy measures. Patients receiving tamsulosin had statistically significant improvement in Qmax, reduction in PVR and IPSS, also in IPSS-QoL but this was not statistically significant. Patients who received tadalafil showed a response in all parameters but with no statistical significance. After 12 weeks of treatment, both groups showed a response in all the efficacy variables and these were
maintained. Patients who received tadalafil showed a statistically significant change from baseline with improvement in Qmax, reduction in IPSS and IPSS-QoL scores. PVR was reduced in the tadalafil group but showed no statistical significance. Patients who received tamsulosin showed further significant efficacy in all the measures, rise in Qmax, reduction in IPSS, IPSS QoL scores and PVR. Maximal urinary flow rate was significantly improved from baseline with both tadalafil and tamsulosin during the treatment period. Tamsulosin treatment resulted in a more significant change from baseline in Qmax of +4 compared to +2.4 in the tadalafil group with statistical significance, p = 0.002. The mean decrease in the residual urine volume in the tadalafil group was 12 ml and in the tamsulosin group was 59 ml. Tamsulosin treatment showed significant reduction in PVR compared to the tadalafil with a p value of 0.004 (Table 2).

IPSS score was improved from the baseline to 12 weeks after treatment in both groups; reduction in IPSS was greater in the tamsulosin group when compared to the tadalafil group, but this was of no statistical significance. The overall mean reduction of IPSS score in the tadalafil group is 0.62 compared to 2.76 IPSS reduction in the tamsulosin group (Table 2). The mean change in quality of life was noted in both groups, but this was not statistically significant, with a mean change from baseline of 0.26 in the tadalafil group and 0.76 in the tamsulosin group.

In this study, 17 patients in the tadalafil group had associated ED and 13 patients had associated ED in the tamsulosin group. The change in the SHIM score in the tadalafil group was 15.53 compared to a baseline of 12.65 and with tamsulosin treatment it was 14.62 compared to a baseline of 13.38. The mean change form baseline SHIM to 12 weeks after initiating treatment was noted in both groups, with tadalafil it was 2.88 (p = 0.001) which is statistically significant and with tamsulosin it was 1.24 (p = 0.217) with no statistical significance (Table 3).

According to our analysis, there was no difference in the mean change from baseline to 12 weeks ob-
PDE5-Is act mainly to relieve the dynamic obstruction of the prostate with a direct relaxation of the bladder [11]. Several in-vitro studies have reported smooth muscle relaxation in the human bladder neck and prostate in the presence of PDE5-Is [12, 13] and relaxation of the bladder neck and decreases in detrusor muscle overactivity.

In a dose-finding study, tadalafil 5 mg was approved to provide a positive risk benefit profile compared with other doses for 12 weeks [14]. The insignificant increase in Qmax for all doses suggested that tadalafil can exert its clinical activity differently compared to the traditional BPH treatment with alpha-blockers. tamsulosin, a uroselective alpha-blocker, relaxes smooth muscle in the prostate and bladder neck, thereby enhancing bladder emptying. In randomized, controlled clinical trials using standardized instruments, tamsulosin improves lower urinary tract symptoms by at least 25% in 65–80% of patients with symptomatic benign prostatic hyperplasia [15]. Antagonism of alpha-1 adrenoreceptors by tamsulosin relaxes the smoothmuscles in the bladder neck and prostate to improve urine flow rate and symptoms of benign prostatic hyperplasia. Oelke et al. reported a significant outcome in Qmax (+2.4 ml/s, p <0.05) in men with a lower baseline obstruction (Qmax at baseline: 9.9 ml/s) with tadalafil, which is similar to our study (+2.4 ml/s, p = 0.001) [2]. Chapple et al. reported the results of a meta-analysis of two multicenter randomized controlled trials, where tamsulosin treated patients had a greater increase in peak urinary flowrate and a more significant decrease in PVR when compared with patients in the placebo group [16].

In our study, when compared to tadalafil, tamsulosin showed more efficacy in raising Qmax. This was on par with Abrams et al. and Lepor et al. who stated that patients treated with tamsulosinexperienced a greater increase in peak urinary flow [17–20]. The lack of a significant peak flow improvement and reduction in PVR in men with LUTS secondary to BPH treated with tadalafil is consistent with pre-

### DISCUSSION

In the presence of moderate or severe LUTS due to BPH, medical management has become the standard of care in patients [7, 8]. Alpha1-adrenoreceptor antagonists (alpha-blockers) were the most widely prescribed drugs, while use of PDE5-Is has been recently gaining popularity for LUTS secondary to BPH. The 2016 Guidelines on the Management of Male LUTS (including benign prostatic obstruction) published by the European Association of Urology (EAU) and guidelines compiled by the American Urological Association (AUA) recommend the use of several different pharmacotherapies for the treatment of LUTS, depending on the clinical situation. Alpha-blockers and 5-ARIs are considered the first-line medical treatment in men with moderate to severe LUTS. The newest drug class, PDE5-Is, are mentioned in the 2013 EAU guidelines [9, 10]. The aim of this study was to make a direct comparison of two medical treatment options for patients with LUTS secondary to BPH in daily clinical practice, that is, the alpha 1-adrenoreceptor antagonist (tamsulosin) and the PDE5-I (tadalafil) which had been less compared directly as monotherapy for LUTS secondary to BPH.

### Table 4. Comparison of mean change in efficacy variables in patients with associated erectile dysfunction between both groups

|                      | Tadalafil (N = 17) | Tamsulosin (N = 13) | P value |
|----------------------|-------------------|---------------------|---------|
| Qmax (ml/sec)        | Baseline 12 weeks | Change from baseline| Baseline 12 weeks | Change from baseline |         |
| 12.38                | 14.55             | +2.17               | 13.62    | 17.56             | +3.94    | 0.0001* |
| PVR (ml)             | 46.1              | 35.2                | -10.9    | 65.7              | 20.3     | -45.4   | 0.0001* |
| IPSS                 | 14.0              | 13.18               | -0.82    | 14.77             | 11.62    | -3.15   | 0.334   |
| IPSS QoL             | 2.71              | 2.47                | -0.24    | 3.0               | 2.38     | -0.62   | 0.238   |
| SHIM                 | 12.65             | 15.53               | +2.88    | 13.38             | 14.62    | +1.24   | 0.028*  |

Qmax – maximum flow rate, PVR – postvoid residual urine, IPSS – International Prostate Symptom Score, IPSS QoL – International Prostate Symptom Score Quality of life, SHIM – Sexual Health Inventory for Men
cially designed to demonstrate efficacy in treating ED, tadalafil showed significant mean change in SHIM when compared to tamsulosin (p = .001 and p = 0.217, respectively), which is consistent with study by Oelke et al. [2]. Notably, improvement in LUTS secondary to BPH after 12 weeks is similar in both groups in men with and without ED, as the p values for treatment by ED status interactions were not significant to that of the overall population. Broderick et al. [31] compared the efficacy of tadalafil in BPH patients with and without ED and reported that the relief in LUTS caused by tadalafil was not influenced by ED according to Alexander Govorov et al. [9], which is similar to our analysis. Bechara and Kaplan reported on PDE5-Is vs. alpha-blockers monotherapy in treating both sexual dysfunction and LUTS, stating that the combination of alpha-blocker and PDE5-I is better in treating LUTS, significantly improved IPSS and IPSS-QoL and associated ED [32, 33]. Although not statistically significant for most sexual function-related items, there is a tendency for tamsulosin to have a better effect on sexual function. Both drugs were very well tolerated in our study. They have an almost negligible rate of adverse events, comparable to Oelke M et al. [2].

CONCLUSIONS

Tamsulosin 0.4 mg once daily for 12 weeks resulted in clinically meaningful improvements in Qmax, PVR, IPSS and IPSS-QoL in patients with LUTS secondary to BPH, which were statistically significant. Tadalafil 5 mg also demonstrated better efficacy on the aforementioned outcomes, which were statistically significant in all the measures except PVR. Tadalafil also showed significant improvement in ED which was not seen with tamsulosin. When both groups were compared, tamsulosin showed better efficacy than tadalafil in treating LUTS secondary to BPH with significant difference in Qmax and PVR between both groups. Our study provides evidence supporting the above-mentioned conclusion and suggests that once daily tadalafil 5 mg is well tolerated and can be considered for the treatment of LUTS secondary to BPH when associated with ED.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.
References

1. Oelke M, Giuliano F, Simin KB, Thomas M, Angelina S et al: Treatment satisfaction with Tadalafil or Tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of Benign Prostatic Hyperplasia (BPH): results from a randomized, placebo-controlled study. BJU Int. 2014; 114: 568-575.

2. Oelke M, Giuliano F, Mirone V, et al. Monotherapy with Tadalafil or Tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo- controlled clinical trial. Eur Urol 2012; 61: 917-925.

3. Hatzimouratidis K. A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction: Ther Adv Urol. 2014; 6: 135-147.

4. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011; 185: 1793-1803.

5. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003; 44: 637-649.

6. Rosen RC, et al. Development and evaluation of an abridged, 5 item version of the International Index of Erectile Function (IIEF) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999; 11: 319-326.

7. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011; 185: 1793-1803.

8. Oelke M, Bachmann A, Descazneau A, et al. EAU guidelines on the treatment and followup of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013; 64: 118-140.

9. Govorov A, Kasyan G, Priymak D, Pushkar D, Sorsaburu S. Tadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia. Cent European J Urol. 2014; 67: 167-177.

10. Kolontarev K, Govorov A, Kasyan G, Priymak D, Pushkar D. Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors. Cent European J Urol. 2016; 6: 398-403.

11. Gacci M, Salvi M, Sebastianelli A, et al. The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction. Res Rep Urol. 2013; 5: 99-111.

12. Filippi S, Morelli A, Sandner P, et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology. 2007; 148: 1019-1029.

13. Morelli A, Sarchielli E, Comeglio P, et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med. 2011; 8: 2746-2760.

14. Claus G. Roehrborn, Kevin T. McVary, Albert Elion-Mboussa, Lars Viktrup. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol. 2008; 180: 1228-1234.

15. Lee M. Tamsulosin for the treatment of Benign Prostatic Hypertrophy. Ann Pharmacother. 2000; 34: 188-199.

16. Chapple CR. Selective alpha-1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol. 1996; 29: 129-144.

17. Lepor H, Williford WO, Barry MJ, et al. for the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The impact of medical therapy on bother due to symptom, quality of life and global outcome, and factors predicting response. J Urol. 1998; 160: 1358-1367.

18. Schulman CC, Corteiendi J, Jonas U, et al. For the European Tamsulosin Study Group. Tamsulosin, the first prostate selective 1a-adrenoceptor antagonist. Analysis of a multinational, multicenter, open-label study assessing the long term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol. 1996; 29: 145-154.

19. Narayan P, Tewari A. A second Phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol. 1998; 160: 1701-1706.

20. Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective 1a-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol. 1995; 76: 325-336.

21. McVary, KT. Unexpected insights into pelvic function following phosphodiesterase manipulation-what’s next for urology? Eur Urol. 2006; 50: 1153-1156.

22. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008; 53: 1236-1244.

23. Nordling J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int. 2005; 95: 1006-1012.

24. Dunn CJ, Matheson A and Faulds DM. Tamsulosin: A review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging. 2002; 19: 135-161.

25. Porst H, McVary KT, Montorsi F, et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol. 2009; 56: 727-735.

26. Porst H, Kim ED, Casabe AR, et al. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol. 2011; 60: 1105-1113.

27. Kim SD, Park JW. Role of phosphodiesterase type 5 inhibitor on benign prostatic hyperplasia/lower urinary tract symptoms. Korean J Androl. 2011; 29: 91-100.

28. Takeda M, Nishizawa O, Imaoka T, Morisaki Y, Viktrup L. LVIA: Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign
prostatic hyperplasia; results from a 12 week placebo controlled dose finding study and a 42 week open label extension. LUTS. 2012; 3: 110-119.

29. Yokoyama O, Yoshida M, Kim SC, et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized placebo and tamsulosin controlled 12 week study in Asian men. Int J Urol. 2013; 20: 193-201.

30. Kawabe K, Yoshida M, Homma Y. Silodosin, a new alpha1A-adrenoceptor selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo controlled, double blind study in Japanese men. BJU Int. 2006; 98: 1019-1024.

31. Tsukamoto T, Endo Y, Narita M. Efficacy and safety of dutasteride in Japanese men with benign prostatic hyperplasia. Int J Urol. 2009; 16: 745-750.

32. Bechara A, Romano S, Casabe A, et al. Comparative Efficacy Assessment of Tamsulosin vs Tamsulosin Plus Tadalafil in the treatment of LUTS/BPH. Pilot Study. J Sex Med. 2008; 5: 2170-2178.

33. Kaplan SA, Hatzichristou D. Open to debate. The motion: PDE5 inhibitors will have a significant role in the treatment of BPH. Eur Urol. 2007; 52: 1523-1527.